Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4573 Comments
630 Likes
1
Mylinh
Registered User
2 hours ago
Are you secretly training with ninjas? 🥷
👍 58
Reply
2
Janaris
Legendary User
5 hours ago
This feels like something I forgot.
👍 223
Reply
3
Misaki
Active Reader
1 day ago
I feel like I missed something obvious.
👍 101
Reply
4
Antuwan
Legendary User
1 day ago
Interesting read — gives a clear picture of the current trends.
👍 131
Reply
5
Hemant
Active Reader
2 days ago
This would’ve changed my whole approach.
👍 13
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.